Next 10 |
home / stock / cotqf / cotqf news
TORONTO and BOSTON, July 18, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
TORONTO and BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
TORONTO and BOSTON, June 04, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today an...
TORONTO and BOSTON, May 22, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced...
Preliminary data from a Phase 1b/2a clinical trial evaluating Cotinga Pharmaceuticals' ( OTCQB:COTQF +1.6% ) lead candidate COTI-2, combined with the chemo agent cisplatin, in patients with p53-mutated solid tumors showed a favorable safety profile while two subjects experienced eithe...
TORONTO and BOSTON, May 08, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today th...
TORONTO and BOSTON, April 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, re...
TORONTO and BOSTON, March 19, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today a...
TORONTO and BOSTON, Feb. 26, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
News, Short Squeeze, Breakout and More Instantly...
Cotinga Pharmaceuticals Inc Company Name:
COTQF Stock Symbol:
OTCMKTS Market:
TORONTO and BOSTON, July 18, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...
TORONTO and BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”) , a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today t...